| Literature DB >> 33415686 |
Tzer-Bin Lin1,2,3, Hsien-Yu Peng4, Ming-Chun Hsieh5, Yu-Cheng Ho6, Cheng-Yuan Lai5, Hsueh-Hsiao Wang5, Po-Sheng Yang5,7, Jen-Kun Cheng5,8, Gin-Den Chen9,10, Soo-Cheen Ng9,10, An-Sheng Lee5, Kuang-Wen Tseng5.
Abstract
Many epigenetic regulators are involved in pain-associated spinal plasticity. Coactivator-associated arginine methyltransferase 1 (CARM1), an epigenetic regulator of histone arginine methylation, is a highly interesting target in neuroplasticity. However, its potential contribution to spinal plasticity-associated neuropathic pain development remains poorly explored. Here, we report that nerve injury decreased the expression of spinal CARM1 and induced allodynia. Moreover, decreasing spinal CARM1 expression by Fbxo3-mediated CARM1 ubiquitination promoted H3R17me2 decrement at the K+ channel promoter, thereby causing K+ channel epigenetic silencing and the development of neuropathic pain. Remarkably, in naïve rats, decreasing spinal CARM1 using CARM1 siRNA or a CARM1 inhibitor resulted in similar epigenetic signaling and allodynia. Furthermore, intrathecal administration of BC-1215 (a novel Fbxo3 inhibitor) prevented CARM1 ubiquitination to block K+ channel gene silencing and ameliorate allodynia after nerve injury. Collectively, the results reveal that this newly identified spinal Fbxo3-CARM1-K+ channel gene functional axis promotes neuropathic pain. These findings provide essential insights that will aid in the development of more efficient and specific therapies against neuropathic pain.Entities:
Keywords: CARM1; Fbxo3; Histone arginine methylation; neuropathic pain; spinal
Mesh:
Substances:
Year: 2021 PMID: 33415686 PMCID: PMC8423947 DOI: 10.1007/s13311-020-00977-5
Source DB: PubMed Journal: Neurotherapeutics ISSN: 1878-7479 Impact factor: 7.620